Abstract
The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.
Keywords: P-glycoprotein, multidrug resistance, nanotechnology, drug delivery, therapeutic nanoparticles, cancer chemotherapy.
Current Pharmaceutical Design
Title:Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Volume: 19 Issue: 37
Author(s): Qiu Zhang and Fei Li
Affiliation:
Keywords: P-glycoprotein, multidrug resistance, nanotechnology, drug delivery, therapeutic nanoparticles, cancer chemotherapy.
Abstract: The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.
Export Options
About this article
Cite this article as:
Zhang Qiu and Li Fei, Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/1381612811319370009
DOI https://dx.doi.org/10.2174/1381612811319370009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Current Signal Transduction Therapy Editorial [Hot Topic: Advanced Imagings of Wallerian Degeneration, Pancreatobiliary System, Uterine Cervical Cancer, Periventricular Leukomalacia, Living Cells as well as MR Contrast Agent and QC of SPECT/CT]
Current Medical Imaging Phytochemical Content and Potential Health Applications of Pecan [<i>Carya illinoinensis</i> (Wangenh) K. Koch] Nutshell
Current Topics in Medicinal Chemistry Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA The mRNA-HPV Test Utilization in the Follow Up of HPV Related Cervical Lesions
Current Pharmaceutical Design Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design Expression and Prognostic Significance of the MMP Family Molecules in Bladder Cancer
Combinatorial Chemistry & High Throughput Screening Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Quality Survival with Fertility after Gynaecological and other Cancers
Current Women`s Health Reviews Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Current Genomics Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Hsp90 Flexibility and Development of its Inhibitors for the Treatment of Cancer
Current Chemical Biology Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?
Current Molecular Medicine The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine